CD133 CAR-HL

CD133 CAR-HL is a second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target CD133 (Prominin-1), a marker for brain tumor-initiating cells (BTICs) in glioblastoma. Developed by researchers at McMaster University and the University of Toronto, the construct utilizes a humanized single-chain variable fragment (scFv) in a Heavy chain-linker-Light chain (HL) orientation. The CAR architecture includes a CD8 leader sequence, a CD8a transmembrane domain, a CD28 costimulatory domain, and a CD3ζ signaling tail. Preclinical studies demonstrate that these CAR-T cells selectively recognize and eliminate CD133-positive glioblastoma cells, which are often associated with treatment resistance and disease recurrence. The HL orientation was specifically evaluated alongside an LH orientation to optimize antigen binding and cytotoxic efficiency.

Other names

CD133-specific CAR-T cellsCD-133-specific CAR-T cellsCD 133-specific CAR-T cellsanti-CD133 CAR-Tanti-CD-133 CAR-Tanti-CD 133 CAR-T